SPRR3 Antibody

What is SPRR3 and what are its primary biological functions?

SPRR3, also known as small proline-rich protein 3 (alternative names: SPRC, 22 kDa pancornulin, Cornifin beta, Esophagin), functions primarily as a cross-linked envelope protein of keratinocytes . Recent research has revealed its significant role in allergic airway inflammation, particularly in asthma pathogenesis. SPRR3 regulates the IL-33/ILC2 (group 2 innate lymphoid cells) axis and influences type 2 cytokine expression, making it a critical component in inflammatory signaling pathways . Bioinformatics analyses of GEO databases have confirmed SPRR3 upregulation in asthmatic conditions, suggesting its potential as a therapeutic target .

How do I select the appropriate SPRR3 antibody for my immunohistochemistry experiments?

When selecting an SPRR3 antibody for immunohistochemistry, consider the following methodological criteria:

• Target species compatibility: Verify the antibody has been validated for your species of interest. For instance, some antibodies like the rabbit polyclonal SPRR3 antibody (ab218131) have been specifically validated for human samples in IHC-P applications .

• Epitope recognition: Choose antibodies that target well-conserved regions of the protein. The immunogen sequence is critical - antibodies raised against synthetic peptides within Human SPRR3 aa 1-100 conjugated to Keyhole Limpet Haemocyanin have demonstrated good specificity .

• Application validation: Confirm the antibody has been tested in your specific application. For IHC-P, look for antibodies with demonstrated performance in formalin-fixed paraffin-embedded tissues .

• Literature citations: Prioritize antibodies that have been cited in peer-reviewed publications, indicating successful use in research settings .

What cellular and tissue expression patterns are characteristic of SPRR3?

SPRR3 shows distinct expression patterns that researchers should account for when designing experiments:

• Normal expression: Primarily found in epithelial cells, particularly in keratinized tissues

• Pathological upregulation: Significantly increased in airway epithelial cells after allergen exposure, particularly with house dust mite (HDM) challenge

• Temporal dynamics: In HDM-stimulated BEAS-2B cells, SPRR3 expression peaks approximately 2 hours after stimulation

• Dose-dependent response: Expression levels correlate with allergen concentration, with optimal induction observed at 40 μg/ml of HDM in in vitro systems

What are the optimal protocols for SPRR3 knockdown in airway epithelial models?

Based on successful experimental approaches in recent studies, the following methodological workflow is recommended for SPRR3 knockdown:

• siRNA design: Target specific conserved regions of the SPRR3 mRNA sequence. In mouse models, intratracheal siRNA delivery has shown effective knockdown .

• Transfection protocol for in vitro studies:

  • Culture BEAS-2B cells to 60-70% confluence

  • Transfect with SPRR3 siRNA (alternatively, use negative control siRNA for comparison)

  • Allow 24-48 hours for efficient knockdown before HDM stimulation

  • Optimal HDM concentration: 40 μg/ml for maximum SPRR3 induction

• In vivo knockdown protocol:

  • Deliver SPRR3 siRNA via intratracheal route before allergen challenge

  • Administer 24-48 hours before HDM challenge

  • Verify knockdown efficiency through immunohistochemistry and Western blotting of lung tissue

• Validation methods:

  • mRNA level: Quantitative PCR

  • Protein level: Western blotting and immunohistochemistry

How should I optimize SPRR3 immunohistochemistry staining protocols for respiratory tissue samples?

For optimal immunohistochemical detection of SPRR3 in respiratory tissues:

• Tissue preparation:

  • Fix tissues in 10% neutral-buffered formalin

  • Process and embed in paraffin

  • Section at 4-5 μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Maintain at 95-98°C for 15-20 minutes

  • Allow slow cooling to room temperature

• Antibody incubation:

  • Block with appropriate serum (5-10%)

  • Use rabbit polyclonal SPRR3 antibody at 1:200 dilution

  • Incubate overnight at 4°C for optimal sensitivity

• Detection and visualization:

  • Secondary antibody conjugation followed by DAB staining

  • Counterstain with hematoxylin for nuclear visualization

  • Mount with permanent mounting medium

• Controls:

  • Include positive control (human laryngocarcinoma tissue has shown strong SPRR3 expression)

  • Include negative control (primary antibody omission)

What flow cytometry protocols are recommended for analyzing SPRR3's impact on inflammatory cell recruitment?

To effectively analyze the impact of SPRR3 on inflammatory cell recruitment using flow cytometry:

• Sample preparation from bronchoalveolar lavage fluid (BALF):

  • Collect BALF through standard lung lavage with PBS

  • Centrifuge at 300g for 5 minutes

  • Resuspend cell pellet in flow cytometry buffer

• Antibody panel for inflammatory cell identification:

  Cell Type	Surface Markers	Gating Strategy
  Eosinophils	CD45+Ly6G−CD11c−SiglecF+	Gate on CD45+Ly6G− cells, then identify CD11c−SiglecF+ population
  Neutrophils	CD45+Ly6G+	Gate on CD45+ cells, then identify Ly6G+ population
  ILC2s	CD45+Thy1.2+Lin−ST2+	Gate on CD45+ cells, then identify Thy1.2+Lin− cells, and analyze ST2+ subset
  CD4+ T cells	CD45+CD3+CD4+	Gate on CD45+ cells, then identify CD3+CD4+ population

• Analysis parameters:

  • Quantify both percentage and absolute number of each cell population

  • Correlate changes with SPRR3 expression/knockdown status

How does SPRR3 modulate the IL-33/ILC2 axis in allergic airway inflammation models?

SPRR3 functions as a critical upstream regulator of type 2 inflammatory responses through several interconnected mechanisms:

• Regulation of epithelial alarmins: SPRR3 positively regulates the expression of IL-25, IL-33, and TSLP in airway epithelial cells. Following HDM exposure, SPRR3 expression increases rapidly, correlating with enhanced production of these epithelial-derived cytokines. SPRR3 knockdown significantly suppresses the expression of these alarmins both in vivo and in vitro .

• Activation of PI3K/AKT/NF-κB signaling: SPRR3 promotes activation of the PI3K/AKT/NF-κB pathway, which is crucial for ILC2 recruitment and activation. Mechanistically, SPRR3 knockdown significantly attenuates the phosphorylation of PI3K, AKT, and NF-κB, demonstrating its role as an upstream modulator of this signaling cascade .

• ILC2 recruitment and activation: Through its regulation of IL-33 expression, SPRR3 indirectly controls ST2-positive ILC2 cell accumulation in the lung. In HDM-induced asthma models, SPRR3 knockdown significantly reduced the percentage of activated ILC2s (characterized as CD45+Thy1.2+Lin−ST2+) .

• Downstream effects on Th2 responses: By modulating the IL-33/ILC2 axis, SPRR3 ultimately influences Th2 cytokine production (IL-4, IL-5, IL-13) and CD4+ T cell recruitment to the airways .

What experimental approaches can be used to investigate the relationship between SPRR3 and the PI3K/AKT/NF-κB signaling pathway?

To thoroughly investigate SPRR3's relationship with the PI3K/AKT/NF-κB pathway, implement these methodological approaches:

• Phosphorylation analysis:

  • Western blot analysis of phosphorylated PI3K, AKT, and NF-κB in lung tissues and cultured cells

  • Compare phosphorylation status between control, HDM-challenged, and SPRR3-knockdown conditions

  • Use phospho-specific antibodies targeting p-PI3K (Tyr458/Tyr199), p-AKT (Ser473), and p-NF-κB p65 (Ser536)

• Inhibitor studies:

  • Utilize specific inhibitors of PI3K (e.g., LY294002), AKT (e.g., MK-2206), or NF-κB (e.g., BAY 11-7082)

  • Assess whether pathway inhibition mimics the effects of SPRR3 knockdown

  • Evaluate if overexpression of SPRR3 can overcome the effects of pathway inhibitors

• Rescue experiments:

  • In SPRR3-knockdown systems, introduce constitutively active forms of PI3K or AKT

  • Determine if this rescues the inflammatory phenotype

  • Measure downstream cytokine production and inflammatory cell recruitment

• Temporal analysis:

  • Perform time-course experiments to establish the sequence of events

  • Determine whether SPRR3 upregulation precedes PI3K/AKT/NF-κB activation

  • Use both in vitro BEAS-2B cell models and in vivo HDM-challenged mice

How can SPRR3 antibodies be utilized to study epithelial-immune cell interactions in asthma pathogenesis?

SPRR3 antibodies can provide valuable insights into epithelial-immune cell interactions through these advanced research approaches:

• Co-immunofluorescence analysis:

  • Double staining for SPRR3 and epithelial markers (E-cadherin, cytokeratins)

  • Visualize spatial relationships between SPRR3-expressing epithelial cells and immune cell populations (using markers for ILC2s, eosinophils, and CD4+ T cells)

  • Quantify the proximity of immune cells to SPRR3-high versus SPRR3-low epithelial regions

• Airway epithelium-immune cell co-culture systems:

  • Establish air-liquid interface cultures of primary bronchial epithelial cells

  • Manipulate SPRR3 expression using siRNA knockdown or overexpression

  • Co-culture with isolated ILC2s or CD4+ T cells

  • Use SPRR3 antibodies to monitor protein expression and localization during cell-cell interactions

• Immunoprecipitation studies:

  • Utilize SPRR3 antibodies for pull-down assays

  • Identify potential binding partners within the IL-33/ST2 signaling pathway

  • Confirm interactions through reciprocal immunoprecipitation

• Tissue microenvironment analysis:

  • Apply SPRR3 antibodies to lung tissue sections from asthmatic patients and controls

  • Correlate SPRR3 expression with markers of epithelial damage and immune cell infiltration

  • Develop quantitative scoring systems for SPRR3 expression in different microenvironmental contexts

What are the common challenges when using SPRR3 antibodies in mouse models of allergic airway inflammation?

Researchers frequently encounter these challenges when using SPRR3 antibodies in mouse models:

• Species cross-reactivity issues:

  • Many commercially available SPRR3 antibodies are optimized for human samples

  • Solution: Carefully validate antibody cross-reactivity to mouse SPRR3 before experimental use

  • Consider using antibodies raised against conserved epitopes between human and mouse SPRR3

• Background staining in lung tissue:

  • Lung tissue often displays high background due to endogenous peroxidases and biotin

  • Solution: Incorporate additional blocking steps (hydrogen peroxide treatment, avidin/biotin blocking)

  • Use fluorescence-based detection to reduce autofluorescence with appropriate controls

• Temporal expression dynamics:

  • SPRR3 expression changes rapidly after allergen challenge (peaks at approximately 2 hours)

  • Solution: Conduct careful time-course studies to capture the optimal time point for analysis

  • Include multiple time points when studying SPRR3 expression after HDM challenge

• Antibody validation in knockdown models:

  • Confirming the specificity of SPRR3 antibodies in knockdown models

  • Solution: Always include siRNA knockdown controls for antibody validation

  • Use multiple detection methods (Western blot, immunohistochemistry) to confirm specificity

How can I optimize cytokine measurements when studying SPRR3's impact on type 2 inflammatory responses?

For optimal cytokine measurement in SPRR3 research, implement these methodological refinements:

• Sample collection optimization:

  • For BALF: Standardize lavage volume and technique (typically 0.8-1.0 mL PBS × 3 aliquots)

  • For lung tissue: Utilize consistent anatomical sampling locations

  • Process samples immediately or store at -80°C with protease inhibitors

• Detection method selection:

  Method	Advantages	Limitations	Best Application
  ELISA	High specificity, quantitative	Single analyte per assay	When absolute quantification of specific cytokines is required
  Multiplex bead assay	Multiple analytes, small sample volume	Higher cost, potential cross-reactivity	For comprehensive cytokine profiling (IL-4, IL-5, IL-13)
  qPCR	Detects mRNA expression	Not reflective of protein levels	Early response assessment, gene expression studies
  Flow cytometry	Cell-specific cytokine production	Complex protocol, requires fresh samples	For identifying cellular sources of cytokines

• Sensitivity enhancement strategies:

  • Use high-sensitivity ELISA kits for detecting low-abundance cytokines (particularly IL-4)

  • Concentrate BALF samples for improved detection of dilute analytes

  • Implement signal amplification techniques when necessary

• Normalization approaches:

  • For BALF: Normalize to total protein concentration or lavage volume

  • For tissue: Normalize to tissue weight or total RNA/protein

  • Include appropriate housekeeping genes for qPCR normalization

What controls should be included when evaluating SPRR3 knockdown efficiency in experimental models?

To rigorously validate SPRR3 knockdown efficiency, include these essential controls:

• Negative controls:

  • Non-targeting siRNA with similar GC content to SPRR3 siRNA

  • Vehicle-only transfection reagent control

  • PBS control (for in vivo studies)

• Positive controls:

  • Known effective SPRR3 siRNA sequences from published literature

  • Tissue samples with confirmed high SPRR3 expression (e.g., HDM-challenged lung tissue)

• Validation at multiple levels:

  • mRNA level: qPCR with multiple primer pairs targeting different regions of SPRR3 transcript

  • Protein level: Western blot and immunohistochemistry using validated SPRR3 antibodies

  • Functional readouts: Measure downstream targets (IL-33, IL-25, TSLP expression)

• Time-course assessment:

  • Evaluate knockdown efficiency at multiple time points (24h, 48h, 72h post-transfection)

  • Determine the duration of knockdown effect in relation to experimental timeline

How should researchers interpret changes in SPRR3 expression in relation to inflammatory cell profiles in asthma models?

When interpreting SPRR3 expression data in relation to inflammatory cell profiles:

• Correlation analysis framework:

  • Analyze the relationship between SPRR3 expression levels and specific inflammatory cell counts

  • Based on published data, expect positive correlations between SPRR3 expression and:

    • Eosinophil counts in BALF (strongest correlation)

    • ST2+ ILC2 numbers in lung tissue

    • CD4+ T cell recruitment

    • Neutrophil counts (moderate correlation)

• Temporal relationship considerations:

  • SPRR3 upregulation typically precedes inflammatory cell infiltration

  • Peak SPRR3 expression occurs approximately 2 hours after allergen exposure

  • Inflammatory cell recruitment follows (24-48 hours later)

  • This temporal sequence supports SPRR3's role as an upstream regulator

• Dose-response interpretations:

  • Analyze SPRR3 expression in relation to allergen concentration

  • Expect proportional relationships between allergen dose, SPRR3 expression, and inflammatory cell recruitment up to a saturation point

  • Optimal HDM concentration for in vitro studies: 40 μg/ml

• Intervention effect interpretation:

  Intervention	Expected Effect on SPRR3	Expected Effect on Inflammatory Cells
  SPRR3 knockdown	50-70% reduction in protein	Significant decrease in eosinophils, moderate decrease in neutrophils, reduced ST2+ ILC2s and CD4+ T cells
  HDM challenge	3-5 fold increase	Significant increase in all inflammatory cell types
  IL-33 neutralization	Minimal effect on SPRR3	Partially mimics SPRR3 knockdown effects

What statistical approaches are most appropriate for analyzing the effects of SPRR3 knockdown on cytokine profiles?

When analyzing SPRR3 knockdown effects on cytokine profiles, implement these statistical approaches:

• Group comparison methods:

  • For normally distributed data: One-way ANOVA with appropriate post-hoc tests (Tukey or Bonferroni)

  • For non-normally distributed data: Kruskal-Wallis test with Dunn's post-hoc comparison

  • Include at minimum four experimental groups: PBS+NC siRNA, PBS+SPRR3 siRNA, HDM+NC siRNA, HDM+SPRR3 siRNA

  • Report both statistical significance (p-values) and effect sizes

• Sample size considerations:

  • Based on published research, n=4-6 animals per group provides sufficient statistical power

  • For in vitro studies, a minimum of 3 independent experiments is recommended

  • Perform power analysis before experimentation to determine optimal sample size

• Correlation analyses:

  • Perform Pearson's or Spearman's correlation between SPRR3 expression levels and:

    • Individual cytokine levels (IL-4, IL-5, IL-13)

    • Inflammatory cell counts

    • Clinical parameters (airway hyperresponsiveness, mucus production)

• Multivariate approaches:

  • Consider principal component analysis (PCA) to identify patterns in cytokine expression data

  • Use hierarchical clustering to identify cytokine signatures associated with SPRR3 expression levels

  • Implement partial least squares discriminant analysis (PLS-DA) to identify key discriminating variables between SPRR3 normal and knockdown conditions

How can researchers distinguish direct effects of SPRR3 from secondary inflammatory cascade effects in experimental models?

To differentiate between direct SPRR3 effects and secondary inflammatory cascade effects:

• Temporal dissection approach:

  • Design early time-point experiments (2h, 4h, 6h post-challenge)

  • Measure SPRR3 expression alongside immediate downstream targets (IL-25, IL-33, TSLP)

  • Compare to late time-point measurements (24h, 48h, 72h) of secondary inflammatory mediators

  • Direct effects should manifest early, while secondary effects emerge later

• Cell-specific analysis:

  • Perform cell type-specific SPRR3 knockdown (epithelial-specific versus global)

  • Compare resultant phenotypes to determine cell-autonomous versus non-autonomous effects

  • Utilize airway epithelial-specific promoters for targeted manipulation

• Pathway inhibition studies:

  • Combine SPRR3 knockdown with inhibitors of specific downstream pathways:

    • IL-33 receptor (ST2) blockade

    • PI3K/AKT/NF-κB pathway inhibitors

    • ILC2 depletion

  • Additive effects suggest independent mechanisms, while non-additive effects suggest shared pathways

• In vitro recombinant protein studies:

  • Use purified recombinant SPRR3 protein in controlled in vitro systems

  • Measure direct transcriptional and signaling effects in isolated cell populations

  • Compare to effects observed in complex in vivo models

  • This approach helps isolate direct SPRR3-mediated activities from inflammatory amplification loops

What are the key considerations when interpreting SPRR3's role across different asthma endotypes?

When interpreting SPRR3's role across asthma endotypes, consider these critical factors:

• Endotype-specific expression patterns:

  • SPRR3 appears most strongly associated with type 2-high, eosinophilic asthma endotypes

  • GEO database analysis reveals significant SPRR3 upregulation in IL-13-treated airway epithelial cells, supporting its role in type 2 inflammatory pathways

  • Further research is needed to characterize SPRR3 expression in non-type 2 asthma endotypes

• Therapeutic target potential assessment:

  • SPRR3 inhibition shows greatest promise for allergic, eosinophilic asthma subtypes

  • HDM-induced models demonstrate significant benefits of SPRR3 knockdown on airway inflammation

  • Consider combinatorial approaches targeting both SPRR3 and other inflammatory mediators for optimal therapeutic effect

• Biomarker potential:

  • Evaluate SPRR3 expression in relation to established asthma endotype biomarkers

  • Consider SPRR3 as a potential biomarker for identifying patients likely to respond to therapies targeting type 2 inflammation

  • Develop standardized assays for SPRR3 detection in clinical samples

• Translational implications:

  • Careful examination of species differences in SPRR3 biology is essential

  • Current research primarily conducted in mouse models requires validation in human systems

  • Consider developing humanized models to better evaluate SPRR3-targeting therapeutic approaches